| Cat.No. | Name | Information |
|---|---|---|
| M7325 | Rimonabant Hydrochloride | Rimonabant hydrochloride is a cannabinoid receptor antagonist, which binds selectively to central cannabinoid receptors (CB1) with high affinity |
| M45341 | Ajulemic acid | Ajulemic acid is a synthetic, orally available Δ9-tetrahydrocannabinol metabolite and cannabinoid receptor agonist with Ki values of 5.7 nM for hCB1 and 56.1 nM for hCB2, and EC50 values of 11.6 nM and 13.4 nM, respectively. |
| M45340 | WIN 55212-2 | WIN 55212-2 is a non-specific cannabinoid receptor agonist. |
| M45339 | CP 55940 | CP 55940 is a variant full agonist of the CB1 receptor that exhibits high and approximately equal affinity for central and peripheral cannabinoid receptors, with Ki's of 0.6 - 5.0 and 0.7-2.6 nM for CB1 and CB2, respectively, and EC50 values of 0.2 and 0.3 nM for CB1 and CB2, respectively.In addition, when acting on GRP55, the EC50 value is 5 nM. |
| M41793 | AM841 | AM841 is a high-affinity electrophilic ligand. |
| M41792 | CB2 PET Radioligand 1 | CB2 PET Radioligand 1 is a PET Radioligand targeting to hCB2 (Ki=7.7 nM). |
| M41791 | CB-25 | CB-25 is a ligand of CB1 cannabinoid receptors, acting as a partial agonist. |
| M41790 | O-2093 | O-2093 is a selective endocannabinoid anandamide (AEA) reuptake inhibitor with IC50 of 17.3 μM. |
| M41789 | Monlunabant | Monlunabant ( (S)-MRI-1891) is a solid dispersion compound that is also an orally active inhibitor of the cannabinoid CB1 receptor. |
| M41637 | CB1R/AMPK modulator 1 | CB1R/AMPK modulator 1 is an orally active CB1R/AMPK modulator, with an Ki of 0.81 nM and an IC50 of 3.9 nM for CB1R. |
| M40943 | INV-202 | INV-202 is an orally active type 1 cannabinoid receptor (CB1) blocker that blocks the receptor protein CB1 in peripheral tissues such as adipose tissue, gastrointestinal tract, kidneys, liver, pancreas, muscle, and lungs, and can be used in studies related to obesity. |
| M31378 | Auriculasin | Auriculasin is a naturally occurring polyphenolic flavonoid that acts on cannabinoid receptor 1 (CB1) with an IC50 value of 8.92 µM. It is also a potential inhibitor of SOS1-KRAS interactions with anticancer and anti-inflammatory activities. |
| M30911 | CB2 receptor agonist 3 | CB2 receptor agonist 3 is a robust and selective CB2 cannabinoid agonist with Kis of 7.6 and 900 nM for CB2 and CB1, respectively. CB2 receptor agonist 3 significantly increases P-ERK 1/2 expression in HL-60 cells. |
| M30812 | S-777469 | S-777469 is a selective and orally available cannabinoid type 2 receptor (CB2) agonist with a Ki of 36 nM. S-777469 significantly suppresses compound 48/80-induced scratching behavior in mice in a dose-dependent manner. S-777469 produces its antipruritic effects by inhibiting itch signal transmission through CB2 agonism. |
| M30475 | Linoleoyl ethanolamide | Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of [3H]CP-55,940 with Kis of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time. |
| M30392 | KM-233 | KM-233 is a classical cannabinoid with good blood brain barrier penetration. KM-233 possesses a selective affinity for the CB2 receptors relative to THC. KM-233 is effective at reducing U87 glioma tumor burden, and can be used for glioma research. |
| M30287 | RTICBM-189 | RTICBM-189 is a potent, brain-penetrant allosteric modulator of the cannabinoid type-1 (CB1) receptor with a pIC50 of 7.54 in Ca2+ mobilization assay. RTICBM-189 has pIC50s of 5.29 and 6.25 for hCB1 and mCB1, respectively. RTICBM-189 significantly and selectively attenuates the reinstatement of the addictive agent-seeking behavior in rats. |
| M30173 | NESS 0327 | NESS 0327 is a cannabinoid antagonist with high selectivity for the cannabinoid CB1 receptor. NESS 0327 is more than 60,000-fold selective for the CB1 receptor. |
| M30122 | Ibipinabant | Ibipinabant (SLV319) is a potent, selective and orally active antagonist of cannabinoid CB1 receptor, with a Ki of 7.8 nM. Ibipinabant shows more than 1000-fold selectivity for CB1 over CB2 (Ki=7943 nM). Ibipinabant can be used for the research of obesity and diabetic. |
| M29983 | Drinabant | Drinabant (AVE1625) is an orally active CB1 receptor antagonist. Drinabant (AVE1625) inhibits the agonist-stimulated calcium signal with IC50 values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R. |
| M29263 | BAY 38-7271 | BAY 38-7271 is selective and highly potent and cannabinoid CB1/CB2 receptor agonist, with Kis of 1.85 nM and 5.96 nM for recombinant human CB1 receptor and CB2 receptor, respectively. BAY 38-7271 has strong neuroprotective properties. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
